-

Robbins LLP Is Investigating the Officers and Directors of GoHealth, Inc. (GOCO) on Behalf of Shareholders

SAN DIEGO & CHICAGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a class action complaint was filed against GoHealth, Inc. (NASDAQ: GOCO) on behalf of shareholders who acquired GoHealth, Inc. shares pursuant to the Company's July 15, 2020, initial public offering ("IPO"). GoHealth operates a health insurance marketplace.

If you have suffered a loss due to GoHealth's misconduct, click here.

GoHealth (GOCO) Accused of Misleading Shareholders

In September 2019, private equity firm Centerbridge acquired GoHealth for $1.1 billion in equity and cash. According to the complaint, GoHealth reported tremendous growth immediately following the acquisition in preparation for going public, representing that its business model was highly profitable and offered the best lifetime value of commissions per customer acquisition cost of any of its peers.

GoHealth conducted its IPO on July 15, 2020, selling approximately 43.5 million shares for $21.00 per share raising nearly $914 million. However, the complaint alleges that GoHealth's IPO materials were negligently prepared and contained false and misleading statements. Specifically, GoHealth failed to disclose: (i) the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020; (ii) GoHealth suffered from a higher risk of customer churn due to its unique business model; (iii) GoHealth could not retain its customers due to various external and internal factors; (iv) GoHealth had entered into materially less favorable revenue sharing arrangements with its external sales agents; and (v) GoHealth had projected these trends to continue and worsen following the IPO. By September 15, 2020, GoHealth closed at $12.53 per share – a more than 40% decline from its IPO price paid by investors just two months previously.

If you purchased GoHealth, Inc. (GOCO), you have until November 20, 2020, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:

Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against GoHealth settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom